Please find below the results of your literature search request.

If you would like the full text of any of the abstracts included, or would like a further search completed on this topic, please let us know.

We’d appreciate feedback on your satisfaction with this literature search. Please visit http://www.hello.nhs.uk/literature_search_feedback.asp and complete the form.

Thank you

**Literature search results**

<table>
<thead>
<tr>
<th><strong>Search completed for:</strong></th>
<th>16 February 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Search request date:</strong></td>
<td>16 February 2011</td>
</tr>
<tr>
<td><strong>Search completion date:</strong></td>
<td>16 February 2011</td>
</tr>
<tr>
<td><strong>Search completed by:</strong></td>
<td>Marilyn Shaw</td>
</tr>
</tbody>
</table>

**Search details**

Clozapine and schizophrenia

**Resources searched**

NHS Evidence; EMBASE; MEDLINE; PsychINFO;

*Database search terms*: Clozapine, Schizophrenia

*Google search string*:

**Summary**

All the information I had given via an email was ‘Clozapine and schizophrenia’, 2/3 articles as up-to-date as possible. On that basis, I have only searched Psychinfo and EMBASE for 2005- current.

**Guidelines**

*Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care*


*Commissioning Guide: Service for the treatment and management of schizophrenia in adults*


**Evidence-based reviews**
<table>
<thead>
<tr>
<th>Published research</th>
</tr>
</thead>
</table>
| 1. **The initial phase of therapy with clozapine: Beyond white blood cell screening**  
**Author(s):** Cohen D.  
**Citation:** Schizophrenia Research, April 2010, vol./is. 117/2-3(386), 0920-9964 (April 2010) |
| 2. **A randomized controlled trial of ECT in clozapine-refractory schizophrenia**  
**Author(s):** Braga R.J., Mendelowitz A.J., Fink M., Schooler N.R., Bailine S.H., Malur C., Petrides G.  
**Citation:** Biological Psychiatry, April 2009, vol./is. 65/8 SUPPL. 1(212S-213S), 0006-3223 (15 Apr 2009) |
| 3. **Comparative effectiveness of antipsychotics in the treatment of schizophrenia: Guidelines for clinical practice**  
**Author(s):** Tandon R., Mller H.-J., Gaebel W., Leucht S., Falkai P.  
**Citation:** European Archives of Psychiatry and Clinical Neuroscience, September 2009, vol./is. 259/(S48-S49), 0940-1334 (September 2009)  
**Full Text:** Available in fulltext at EBSCO Host |
| 4. **Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia**  
**Author(s):** Edlinger M., Hofer A., Rettenbacher M.A., Baumgartner S., Widschwendter C.G., Kemmler G., Neco N.A., Fleischhacker W.W.  
**Citation:** Schizophrenia Research, September 2009, vol./is. 113/2-3(246-251), 0920-9964 (September 2009) |
| 5. **Clozapine-induced myocarditis after long-term treatment: Case presentation and clinical perspectives**  
**Author(s):** Lang U.E., Willbring M., Von Golitschek R., Schmeisser A., Matschke K., Tugtekin S.M.  
**Citation:** Journal of Psychopharmacology, July 2008, vol./is. 22/5(576-580), 0269-8811;1461-7285 (July 2008) |
| 6. **Agranulocytosis monitoring with Clozapine: To follow guidelines or to attempt therapeutic controversies?**  
**Author(s):** Chandrasekaran P.K.  
**Citation:** Singapore Medical Journal, February 2008, vol./is. 49/2(96-99), 0037-5675 (Feb 2008) |
7. **Clozapine-induced eosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies**

**Author(s):** Zipris P., Melamed Y., Weizman A., Bleich A.

**Citation:** Israel Journal of Psychiatry and Related Sciences, 2007, vol./is. 44/1(54-56), 0333-7308 (2007)

8. **Restarting clozapine after neutropenia: Evaluating the possibilities and practicalities**

**Author(s):** Whiskey E., Taylor D.

**Citation:** CNS Drugs, 2007, vol./is. 21/1(25-35), 1172-7047 (2007)

9. **Augmentation strategies in clozapine-resistant schizophrenia**

**Author(s):** Remington G., Saha A., Chong S.-A., Shammi C.

**Citation:** CNS Drugs, 2005, vol./is. 19/10(843-872), 1172-7047;1172-7047 (2005)

10. Comparison of classical and Clozapine treatment on schizophrenia using positive and negative syndrome scale of schizophrenia (PANSS) and SPECT imaging

**Author(s):** Sharafi M.

**Citation:** International Journal of Medical Sciences, May 2005, vol./is. 2/2(79-86), 1449-1907;1449-1907 (10 May 2005)

11. **Management of clozapine-resistant schizophrenia**

**Author(s):** Kerwin R.W., Bolonna A.

**Citation:** Advances in Psychiatric Treatment, March 2005, vol./is. 11/2(101-106), 1355-5146 (Mar 2005)

12. **Title:** Drug prescription patterns in schizophrenia outpatients: Analysis of data from a German health insurance fund.

**Citation:** Pharmacopsychiatry, March 2009, vol./is. 42/2(66-71), 0176-3679;1439-0795 (Mar 2009)

**Author(s):** Weinbrenner, S, Assion, H.-J, Stargardt, T, Busse, R, Juckel, G, Gericke, C. A

13. **Title:** Major changes in glucose metabolism, including new-onset diabetes, within 3 month after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.

**Citation:** Journal of Clinical Psychiatry, March 2008, vol./is. 69/3(472-479), 0160-6689 (Mar 2008)

**Author(s):** van Winkel, Ruud, De Hert, Marc, Wampers, Martien, Van Eyck,

**Citation**: Schizophrenia Research, September 2008, vol./is. 104/1-3(302-304), 0920-9964 (Sep 2008)

**Author(s)**: Vita, Antonio, Corsini, Paola, Bonomi, Silvia, Sacchetti, Emilio, Cesana, Bruno M

15. **Title**: Clozapine-induced myocarditis after long-term treatment: Case presentation and clinical perspectives.

**Citation**: Journal of Psychopharmacology, July 2008, vol./is. 22/5(576-580), 0269-8811;1461-7285 (Jul 2008)

**Author(s)**: Lang, U. E, Willbring, M, von Golitschek, R, Schmeisser, A, Matschke, K, Malte Tugtekin, S

16. **Title**: Clozapine-induced myocarditis after long-term treatment: Case presentation and clinical perspectives.

**Citation**: Journal of Psychopharmacology, July 2008, vol./is. 22/5(576-580), 0269-8811;1461-7285 (Jul 2008)

**Author(s)**: Lang, U. E, Willbring, M, von Golitschek, R, Schmeisser, A, Matschke, K, Malte Tugtekin, S

17. **Title**: Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.

**Citation**: Progress in Neuro-Psychopharmacology & Biological Psychiatry, August 2007, vol./is. 31/6(1330-1336), 0278-5846 (Aug 2007)

**Author(s)**: Semiz, Umit B, Cetin, Mesut, Basoglu, Cengiz, Ebrinc, Servet, Uzun, Ozcan, Herken, Hasan, Ballibey, Hakan, Algul, Ayhan, Ates, Alpay

18. **Title**: Adverse effects of atypical antipsychotics in the elderly: A review.

**Citation**: Drugs & Aging, 2006, vol./is. 23/12(937-956), 1170-229X (2006)

**Author(s)**: Gareri, Pietro, De Fazio, Pasquale, De Fazio, Salvatore, Marigliano, Norma, Ibbadu, Guido Ferreri, De Sarro, Giovambattista

19. **Title**: Resistant schizophrenia: A challenge and new hopes (What is the effect of atypicals combinations?).

**Citation**: Schizoaffective Disorders: New research., 2006(35-67) (2006)

**Author(s)**: Lerner, Vladimir, Miodownik, Chanoch
20. **Title:** Clozapine agranulocytosis: Mechanism of drug toxicity.

**Citation:** Primary Psychiatry, March 2006, vol./is. 13/3(27-29), 1082-6319 (Mar 2006)

**Author(s):** Robinson, Donald S

21. **Title:** Optimizing Pharmacotherapy to Maximize Outcome in Schizophrenia: Management of Patients With Treatment-Resistant Schizophrenia.

**Citation:** Journal of Clinical Psychiatry, January 2005, vol./is. 66/1(128-129), 0160-6689 (Jan 2005)

**Author(s):** Kane, John M